Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06091865

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Lymphoma (DLBCL) that have not been treated before (called "previously untreated"). Patients with DLBCL that have come back after treatment (called "relapsed"), or have not responded to treatment (called "refractory"), can also participate in this study.

This study will be made up of Part 1A, Part 1B, and Part 2.The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy in Part 2 of the study.

The aim of Part 2 of the study is to see how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab (the comparator drug), and chemotherapy, the current standard of care treatment approved for DLBCL. Standard of care means the usual medication expected and used when receiving treatment for a condition.

The study is looking at several other research questions, including:

* What side effects may happen from taking the study drug when combined with chemotherapy * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * The impact from the study drug on quality of life and ability to complete routine daily activities

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL) Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Liverpool Hospital, Liverpool, New South Wales, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Previously untreated participants for lymphoma with documented Cluster of Differentiation 20+ (CD20+) DLBCL, as described in the protocol OR relapsed or refractory DLBCL, for whom next available standard of care therapy is not available or deemed ineligible according to the investigator (Part 1A only)
  • Measurable disease with at least one nodal lesion or at least one extranodal lesion, as described in the protocol
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2
  • Life expectancy ≥ 12 months
  • International Prognostic Index (IPI) of 3 to 5 (part 1 only) and ≥2 (part 2) for untreated DLBCL only
  • Adequate hematologic and organ function, as defined in the protocol.

Key Exclusion Criteria:

  • Primary Central Nervous System (CNS) lymphoma or known involvement by non-primary CNS NHL and history or current relevant CNS pathology
  • Another active malignancy, significant active disease or medical condition, as described in the protocol
  • Peripheral neuropathy Grade ≥3
  • Treatment with any systemic anti-lymphoma therapy, except for participants with Relapsed/Refractory (R/R) DLBCL and participants with DLBCL transformed from an indolent lymphoma after treatment with systemic anti-lymphoma therapy.
  • Any other therapy or investigational treatment within 28 days or 5 half-lives of the drug, whichever is shorter, prior to the start of study treatment
  • Recent major surgery, prior organ transplantation, or standard radiotherapy, as described in the protocol
  • Allergy/hypersensitivity to study drugs, as described in the protocol
  • Infections such as any active infection (bacterial, viral, fungal, mycobacterial, parasitic or other), active Coronavirus Disease (COVID-19) infection, uncontrolled infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV), Cytomegalovirus (CMV) infection, as described in the protocol.

Note: Other protocol-defined Inclusion/ Exclusion criteria apply

Treatment and study plan

Odronextamab

Drug

Odronextamab will be administered by intravenous (IV) infusion

Other names: REGN1979, Ordspono™

Rituximab

Drug

Rituximab will be administered IV, or subcutaneously (SC)

Other names: RITUXAN®

Cyclophosphamide

Drug

Cyclophosphamide will be administered IV as part of chemotherapy

Other names: Cytoxan®

Doxorubicin

Drug

Doxorubicin will be administered IV as part of chemotherapy

Other names: Adriamycin®

Vincristine

Drug

Vincristine will be administered IV as part of chemotherapy

Other names: Oncovin®, Vincasar PFS®

prednisone/prednisolone

Drug

Prednisone or prednisolone will be administered orally (PO) as part of chemotherapy

Other names: Deltasone®/OMNIPRED®

Primary outcomes

  1. Incidence of Dose Limiting Toxicities (DLTs)

    Time frame: Up to 35 days

    Part 1A

  2. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 2 years

    Part 1

  3. Severity of TEAEs

    Time frame: Up to 2 years

    Part 1

  4. Progression Free Survival (PFS), assessed by Independent Central Review (ICR)

    Time frame: Up to 5 years

    Part 2

Secondary outcomes

  1. Event-Free Survival (EFS) assessed by ICR

    Time frame: Up to 5 years

    Part 2

  2. Complete Response (CR) assessed by ICR

    Time frame: Up to 22 weeks

    Part 2

  3. Overall Survival (OS)

    Time frame: Up to 5 years

    Part 2

  4. Best Overall Response (BOR) as assessed by local investigators

    Time frame: Up to 22 weeks

    Part 1 and Part 2

  5. CR as assessed by local investigators

    Time frame: Up to 22 weeks

    Part 1 and Part 2

  6. Duration of Response (DOR) as assessed by local investigators

    Time frame: Up to 5 years

    Part 1 and Part 2

  7. Odronextamab concentrations in serum when administered with CHOP

    Time frame: Up to 22 weeks

    Part 1 and Part 2

  8. Occurrence of Anti-Drug Antibodies (ADA) to odronextamab

    Time frame: Up to 22 weeks

    Part 1 and Part 2

  9. Magnitude of ADA to odronextamab

    Time frame: Up to 22 weeks

    Part 1 and Part 2

  10. PFS assessed by local investigator review

    Time frame: Up to 5 years

    Part 2

  11. EFS assessed by local investigator review

    Time frame: Up to 5 years

    Part 2

  12. BOR assessed by ICR

    Time frame: Up to 22 weeks

    Part 2

  13. DOR assessed by ICR

    Time frame: Up to 5 years

    Part 2

  14. Incidence of TEAEs

    Time frame: Up to 2 years

    Part 2

  15. Severity of TEAEs

    Time frame: Up to 2 years

    Part 2

  16. Minimal Residual Disease (MRD) status

    Time frame: Up to 22 weeks

    Part 2

  17. Change in physical functioning as measured by European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C) 30

    Time frame: Up to 5 years

    Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden.

  18. Change in patient reported outcomes, as measured by EORTC QLQ-C30

    Time frame: Up to 5 years

    Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden.

  19. Change in patient reported outcomes, as measured by Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS)

    Time frame: Up to 5 years

    Part 2 The FACT-Lym lymphoma subscale (LymS) includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life.

  20. Change in patient reported outcomes, as measured by Patient Global Impression of Severity (PGIS)

    Time frame: Up to 5 years

    Part 2 The PGIS includes a single-item to assess how a patient perceives the overall severity of cancer symptoms over the past 7 days. Patients will choose the response that best describes the severity of their overall cancer symptoms with options on a 5-point scale ranging from 1 (No symptoms) to 4 (Very Severe).

  21. Change in patient reported outcomes, as measured by Patient Global Impression of Change (PGIC)

    Time frame: Up to 5 years

    Part 2 The PGIC item includes a single-item to assess how a patient perceives their overall change in health status since the start of study treatment. Patients will choose from response options on a 7-point scale ranging from 1 (Much Better) to 7 (Much worse); 1- Much Better, 2-Moderately Better, 3-A Little Better, 4-About the Same, 5-A Little Worse, 6-Moderately Worse, 7-Much Worse.

  22. Change in patient reported outcomes, as measured by EuroQol-5 Dimension-5 Level Scale (EQ-5D-5L)

    Time frame: Up to 5 years

    Part 2 The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state".

  23. Change in score of the Functional Assessment of Cancer Therapy-General (FACT-G ) GP5 item

    Time frame: Up to 5 years

    Part 2 A single item (GP5) of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4).

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Trials Administrator

CONTACT

[email protected]

844-734-6643

Sponsors and collaborators

Lead sponsor

Regeneron Pharmaceuticals

Industry

Registry information

Official study title

A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (ODRO-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)

Acronym: OLYMPIA-3

Important dates

Study start
2023
Primary completion
2028
Study completion
2029
First posted
Oct 19, 2023
Registry last updated
Jul 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.